JP7515137B2 - ケイ酸塩系基材と希土類化合物との複合体、発光ナノ粒子、細胞の検出方法、動物の治療方法、医療装置、及びケイ酸塩系基材と希土類化合物との複合体の製造方法 - Google Patents

ケイ酸塩系基材と希土類化合物との複合体、発光ナノ粒子、細胞の検出方法、動物の治療方法、医療装置、及びケイ酸塩系基材と希土類化合物との複合体の製造方法 Download PDF

Info

Publication number
JP7515137B2
JP7515137B2 JP2020046605A JP2020046605A JP7515137B2 JP 7515137 B2 JP7515137 B2 JP 7515137B2 JP 2020046605 A JP2020046605 A JP 2020046605A JP 2020046605 A JP2020046605 A JP 2020046605A JP 7515137 B2 JP7515137 B2 JP 7515137B2
Authority
JP
Japan
Prior art keywords
silicate
rare earth
diffraction peak
earth compound
base material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020046605A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021147255A5 (cg-RX-API-DMAC10.html
JP2021147255A (ja
Inventor
直 茶谷
正彦 犬井
基博 多賀谷
卓也 片岡
智 本塚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohara Inc
Nagaoka University of Technology
Institute of National Colleges of Technologies Japan
Original Assignee
Ohara Inc
Nagaoka University of Technology
Institute of National Colleges of Technologies Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohara Inc, Nagaoka University of Technology, Institute of National Colleges of Technologies Japan filed Critical Ohara Inc
Priority to JP2020046605A priority Critical patent/JP7515137B2/ja
Priority to CN202180021205.6A priority patent/CN115362128A/zh
Priority to US17/911,552 priority patent/US20230142721A1/en
Priority to PCT/JP2021/010645 priority patent/WO2021187492A1/ja
Priority to EP21771217.3A priority patent/EP4122886B1/en
Publication of JP2021147255A publication Critical patent/JP2021147255A/ja
Publication of JP2021147255A5 publication Critical patent/JP2021147255A5/ja
Application granted granted Critical
Publication of JP7515137B2 publication Critical patent/JP7515137B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent materials, e.g. electroluminescent or chemiluminescent
    • C09K11/08—Luminescent materials, e.g. electroluminescent or chemiluminescent containing inorganic luminescent materials
    • C09K11/77—Luminescent materials, e.g. electroluminescent or chemiluminescent containing inorganic luminescent materials containing rare earth metals
    • C09K11/7728—Luminescent materials, e.g. electroluminescent or chemiluminescent containing inorganic luminescent materials containing rare earth metals containing europium
    • C09K11/77342—Silicates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A61K49/0067—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B33/00—Silicon; Compounds thereof
    • C01B33/113—Silicon oxides; Hydrates thereof
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent materials, e.g. electroluminescent or chemiluminescent
    • C09K11/02—Use of particular materials as binders, particle coatings or suspension media therefor
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent materials, e.g. electroluminescent or chemiluminescent
    • C09K11/08—Luminescent materials, e.g. electroluminescent or chemiluminescent containing inorganic luminescent materials
    • C09K11/77—Luminescent materials, e.g. electroluminescent or chemiluminescent containing inorganic luminescent materials containing rare earth metals
    • C09K11/7728—Luminescent materials, e.g. electroluminescent or chemiluminescent containing inorganic luminescent materials containing rare earth metals containing europium
    • C09K11/7732—Halogenides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/552—Glass or silica
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Luminescent Compositions (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Radiation-Therapy Devices (AREA)
  • Silicon Compounds (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
JP2020046605A 2020-03-17 2020-03-17 ケイ酸塩系基材と希土類化合物との複合体、発光ナノ粒子、細胞の検出方法、動物の治療方法、医療装置、及びケイ酸塩系基材と希土類化合物との複合体の製造方法 Active JP7515137B2 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2020046605A JP7515137B2 (ja) 2020-03-17 2020-03-17 ケイ酸塩系基材と希土類化合物との複合体、発光ナノ粒子、細胞の検出方法、動物の治療方法、医療装置、及びケイ酸塩系基材と希土類化合物との複合体の製造方法
CN202180021205.6A CN115362128A (zh) 2020-03-17 2021-03-16 硅酸盐基质和稀土类化合物的复合体、发光纳米颗粒、细胞的检测方法、动物的治疗方法、医疗装置以及硅酸盐基质和稀土类化合物的复合体的制造方法
US17/911,552 US20230142721A1 (en) 2020-03-17 2021-03-16 Composite of Silicate-Based Base Material and Rare-Earth Compound, Light-Emitting Nanoparticle, Cell Detection Method, Treating Method for Treating Non-Human Animal, Medical Device, and Method for Producing Composite of Silicate-Based Base Material and Rare-Earth Compound
PCT/JP2021/010645 WO2021187492A1 (ja) 2020-03-17 2021-03-16 ケイ酸塩系基材と希土類化合物との複合体、発光ナノ粒子、細胞の検出方法、動物の治療方法、医療装置、及びケイ酸塩系基材と希土類化合物との複合体の製造方法
EP21771217.3A EP4122886B1 (en) 2020-03-17 2021-03-16 Complex between silicate-based substrate and rare earth element compound, light-emitting nano particles, cell detection method, and method for producing complex between silicate-based substrate and rare earth element compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020046605A JP7515137B2 (ja) 2020-03-17 2020-03-17 ケイ酸塩系基材と希土類化合物との複合体、発光ナノ粒子、細胞の検出方法、動物の治療方法、医療装置、及びケイ酸塩系基材と希土類化合物との複合体の製造方法

Publications (3)

Publication Number Publication Date
JP2021147255A JP2021147255A (ja) 2021-09-27
JP2021147255A5 JP2021147255A5 (cg-RX-API-DMAC10.html) 2023-02-16
JP7515137B2 true JP7515137B2 (ja) 2024-07-12

Family

ID=77771019

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020046605A Active JP7515137B2 (ja) 2020-03-17 2020-03-17 ケイ酸塩系基材と希土類化合物との複合体、発光ナノ粒子、細胞の検出方法、動物の治療方法、医療装置、及びケイ酸塩系基材と希土類化合物との複合体の製造方法

Country Status (5)

Country Link
US (1) US20230142721A1 (cg-RX-API-DMAC10.html)
EP (1) EP4122886B1 (cg-RX-API-DMAC10.html)
JP (1) JP7515137B2 (cg-RX-API-DMAC10.html)
CN (1) CN115362128A (cg-RX-API-DMAC10.html)
WO (1) WO2021187492A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7554424B2 (ja) 2020-03-17 2024-09-20 株式会社オハラ ユーロピウム化合物の結晶体及びユーロピウム化合物の結晶体の製造方法
CN114295664A (zh) * 2021-12-16 2022-04-08 中国煤炭地质总局勘查研究总院 一种利用阴极发光检测矿物中稀土元素的方法
CN120769988A (zh) * 2023-02-24 2025-10-10 株式会社小原 蛋白质固定化用载体、蛋白质固定化用载体分散液、蛋白质固定化用载体水合物、蛋白质担载复合体以及抗体试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521208A (ja) 2010-03-02 2013-06-10 ヘレウス クオーツ ユーケー リミティド 合成シリカガラスの製造

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641288B (zh) * 2007-03-27 2013-07-03 扶桑化学工业株式会社 胶态二氧化硅及其制造方法
KR100943839B1 (ko) 2007-10-31 2010-02-24 한국과학기술연구원 불규칙 표면구조의 우선 도입에 의해 고수율의바이오-이미지용 나노입자를 제조하는 방법
JP2009190976A (ja) 2008-02-12 2009-08-27 Univ Of Tokyo 水分散性量子ドット
JP2010133887A (ja) 2008-12-08 2010-06-17 Yamaguchi Univ 水溶性高効率二光子吸収材料
JP2013014651A (ja) 2011-07-01 2013-01-24 Tokyo Institute Of Technology 蛍光粒子およびその製造方法
JP5790352B2 (ja) 2011-09-09 2015-10-07 コニカミノルタ株式会社 蛍光物質内包ナノ粒子およびこれを用いた生体物質の検出方法
JP6474212B2 (ja) * 2014-08-19 2019-02-27 学校法人東京理科大学 中空シリカ粒子の製造方法及び中空シリカ粒子
JP6820154B2 (ja) 2016-03-28 2021-01-27 株式会社オハラ 発光ナノ粒子、それを用いた細胞の検出方法、動物の治療方法、医療装置、細胞の可視化方法、及び細胞の損傷軽減方法
CN107311217B (zh) * 2017-07-24 2020-02-18 吉林大学 一种磁性/荧光双功能的EuCl2纳米晶以及超晶格结构的EuCl2纳米晶
JP7259231B2 (ja) * 2018-08-31 2023-04-18 堺化学工業株式会社 粒子状シリカ及びその製造方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521208A (ja) 2010-03-02 2013-06-10 ヘレウス クオーツ ユーケー リミティド 合成シリカガラスの製造

Also Published As

Publication number Publication date
EP4122886A1 (en) 2023-01-25
EP4122886A4 (en) 2024-03-20
EP4122886B1 (en) 2025-09-03
US20230142721A1 (en) 2023-05-11
CN115362128A (zh) 2022-11-18
JP2021147255A (ja) 2021-09-27
WO2021187492A1 (ja) 2021-09-23

Similar Documents

Publication Publication Date Title
Escudero et al. Microwave-assisted synthesis of biocompatible europium-doped calcium hydroxyapatite and fluoroapatite luminescent nanospindles functionalized with poly (acrylic acid)
Xue et al. Monodisperse photoluminescent and highly biocompatible bioactive glass nanoparticles for controlled drug delivery and cell imaging
US20230114986A1 (en) Light-emitting nanoparticles, cell detection method using same, animal treatment method, medical device, cell visualization method, and method for reducing injury to cell
EP2233437A1 (en) Nanofunctional silica particles and manufacturing method thereof
EP4122886B1 (en) Complex between silicate-based substrate and rare earth element compound, light-emitting nano particles, cell detection method, and method for producing complex between silicate-based substrate and rare earth element compound
JPWO2010016289A1 (ja) 量子ドットを含有する蛍光標識剤
Zhang et al. Facile synthesis of functional gadolinium-doped CdTe quantum dots for tumor-targeted fluorescence and magnetic resonance dual-modality imaging
Yang et al. Short-wave near-infrared emissive GdPO4: Nd3+ theranostic probe for in vivo bioimaging beyond 1300 nm
Rao et al. One-pot synthesis of PEG modified BaLuF5: Gd/Yb/Er nanoprobes for dual-modal in vivo upconversion luminescence and X-ray bioimaging
CN104174868A (zh) 一种以紫外光还原银氨溶液制备水溶性银纳米簇的方法
Lakshmi et al. Bone tissue regeneration potential of Tb³⁺ ion-integrated silico-gallate mesoporous bioactive glasses
Phuong et al. SCN–IgG functionalized NaYF4: Yb3+/(Er3+, Tm3+) upconversion nanoparticles for targeted fluorescence imaging of liver cancer cells
CN105950150B (zh) 一种核壳型多功能纳米材料及其制备方法
JP7554424B2 (ja) ユーロピウム化合物の結晶体及びユーロピウム化合物の結晶体の製造方法
Gupta et al. KLa (0.95− x) Gd x F4: Eu3+ hexagonal phase nanoparticles as luminescent probes for in vitro Huh-7 cancer cell imaging
Guo et al. Tracking the transformations of mesoporous microspheres of calcium silicate hydrate at the nanoscale upon ibuprofen release: a XANES and STXM study
JPWO2012128162A1 (ja) 画像診断用シリカナノ粒子、その製造方法、及び生体物質標識剤
JP5168092B2 (ja) 半導体ナノ粒子標識剤
JP7096557B2 (ja) 発光ナノ粒子、それを用いた細胞の検出方法、動物の治療方法、医療装置、細胞の可視化方法、及び細胞の損傷軽減方法
CN116656340B (zh) 一种荧光纳米材料及其制备方法与应用
Gupta et al. Nanophosphors‐Nanogold Immunoconjugates in Isolation of Biomembranes and in Drug Delivery
Rezvani Baboli Production of brighter nanoparticles for optical imaging
片岡卓也 Study on Synthesis of Luminescent Hydroxyapatite Nanoparticles and Their Surface Functionalization for Cell Labeling Applications
WO2009150879A1 (ja) 半導体ナノ粒子蛍光体
Kohla et al. Biocompatibility of Eu3+-doped Gadolinium Hydroxide and Oxide Nanorods

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240611

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240624

R150 Certificate of patent or registration of utility model

Ref document number: 7515137

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150